Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
about
Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.Prostate cancer trends in Asia.Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
P2860
Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical outcomes and nadir pr ...... or metastatic prostate cancer.
@en
type
label
Clinical outcomes and nadir pr ...... or metastatic prostate cancer.
@en
prefLabel
Clinical outcomes and nadir pr ...... or metastatic prostate cancer.
@en
P2093
P2860
P1476
Clinical outcomes and nadir pr ...... or metastatic prostate cancer.
@en
P2093
Atsushi Mizokami
Hideyuki Akaza
Kouji Izumi
Mikio Namiki
Satoru Ueno
Shiro Hinotsu
Yasuhide Kitagawa
Yoshifumi Kadono
P2860
P2888
P304
P356
10.1007/S00345-015-1621-5
P577
2015-06-19T00:00:00Z
P6179
1010795764